DK1931710T3 - Konstruerede anti-il-23-antistoffer - Google Patents

Konstruerede anti-il-23-antistoffer Download PDF

Info

Publication number
DK1931710T3
DK1931710T3 DK06802592.3T DK06802592T DK1931710T3 DK 1931710 T3 DK1931710 T3 DK 1931710T3 DK 06802592 T DK06802592 T DK 06802592T DK 1931710 T3 DK1931710 T3 DK 1931710T3
Authority
DK
Denmark
Prior art keywords
ser
gly
leu
thr
val
Prior art date
Application number
DK06802592.3T
Other languages
English (en)
Inventor
Leonard G Presta
Peter Orth
Brian M Beyer
Yan-Hui Liu
Richard N Ingram
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1931710(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of DK1931710T3 publication Critical patent/DK1931710T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (17)

  1. KONSTRUEREDE ANTI-IL-23-ANTISTOFFER
    1. Antistof, eller antigenbindende fragment deraf, der binder til humant IL-23pl9 ved en epitop, der omfatter resterne 82-95 og resterne 133-140 ifølge SEQ ID NO: 29.
  2. 2. Antistof, eller antigenbindende fragment deraf, ifølge krav 1, der binder til en epitop, der omfatter resterne E82, G86, S87, D88, T91, G92, E93, P94, S95, H106, P133, S134, Q135, P136, W137, R139 og L140 ifølge SEQ ID NO: 29.
  3. 3. Antistof, eller antigenbindende fragment deraf, ifølge krav 1, hvor antistoffet omfatter: en CDRL1, der består af resterne 43 - 53 ifølge SEQ ID NO: 4; en CDRL2, der består af resterne 69 - 75 ifølge SEQ ID NO: 4; en CDRL3, der består af resterne 108 - 116 ifølge SEQ ID NO: 4; en CDRH1, der består af resterne 45 - 54 ifølge SEQ ID NO: 3; en CDRH2, der består af resterne 69 - 85 ifølge SEQ ID NO: 3 og en CDRH3, der består af resterne 118 - 123 ifølge SEQ ID NO: 3.
  4. 4. Antistof, eller antigenbindende fragment deraf, ifølge krav 3, hvor: den variable letkæderegion af antistoffet, eller det bindende fragment deraf, omfatter sekvensen af resterne 20-129 ifølge SEQ ID NO: 4, eller en variant deraf; og den variable tungkæderegion af antistoffet, eller det bindende fragment deraf, omfatter sekvensen af resterne 20-134 ifølge SEQ ID NO: 3, eller en variant deraf; hvor varianten omfatter op til 20 konservativt modificerede aminosyresubstitutioner.
  5. 5. Antistof, eller antigenbindende fragment deraf, ifølge krav 4, hvor den bindende forbindelse er et antistof eller bindende fragment deraf, omfattende: en variabel letkæderegion, der omfatter resierne 20-129 ifølge SEQ ID NO: 4 og en variabel tungkæderegion, der omfatter resterne 20-134 SEQ ID NO: 3.
  6. 6. Antistof, eller antigenbindende fragment deraf, ifølge krav 3, der blokerer IL-23-medieret aktivitet.
  7. 7. Isoleret nukleinsyre, der koder for den variable letkæderegion og variable tungkæderegion af antistoffet, eller det antigenbindende fragment deraf, ifølge krav 4.
  8. 8. Ekspressionsvektor, der omfatter nukleinsyren ifølge krav 7 operativt bundet til styrings sekvenser, der genkendes af en værtscelle, når værtscellen er transficeret med vektoren.
  9. 9. Værtscelle, der omfatter ekspressionsvektoren ifølge krav 8.
  10. 10. Fremgangsmåde til fremstilling af et polypeptid, hvilken fremgangsmåde omfatter: dyrkning af værtscellen ifølge krav 9 i et dyrkningsmedium under forhold, hvor nukleinsyresekvensen udtrykkes, hvorved der fremstilles polypeptider, der omfatter de variable let- eller tungkæderegioner; og genvinding af polypeptiderne fra værtscellen eller dyrkningsmediet.
  11. 11. Antistof, eller antigenbindende fragment deraf, ifølge krav 2, der omfatter en konstant region af den humane tungkæde γΐ.
  12. 12. Antistof, eller antigenbindende fragment deraf, ifølge krav 2, der omfatter en konstant region af den humane tungkæde γ4.
  13. 13. Antistof, eller antigenbindende fragment deraf, ifølge krav 1, der omfatter et antistoffragment, der er udvalgt fra gruppen bestående af Fab, Fab', Fab'-SH, Fv, scFv, F(ab')2 og et diabody.
  14. 14. Sammensætning, der omfatter antistoffet, eller det antigenbindende fragment deraf, ifølge krav 4 i kombination med en farmaceutisk acceptabel bærer eller fortynder.
  15. 15. Sammensætning ifølge krav 14, der endvidere omfatter et immunsuppressivt eller anti-inflammatorisk middel.
  16. 16. Værtscelle, der omfatter: (a) en ekspressionsvektor, der omfatter en nukleinsyresekvens, der koder for letkæden af antistoffet, eller det antigenbindende fragment deraf, ifølge krav 4; og (b) en ekspressionsvektor, der omfatter en nukleinsyresekvens, der koder for tungkæden af antistoffet, eller det antigenbindende fragment deraf, ifølge krav 4.
  17. 17. Fremgangsmåde til fremstilling af en bindende forbindelse, hvilken fremgangsmåde omfatter: dyrkning af værtscellen ifølge krav 16 i dyrkningsmedium under forhold, hvor nukleinsyresekvenseme udtrykkes, hvorved der fremstilles polypeptider, der omfatter let- eller tungkædeme af antistoffet, eller det antigenbindende fragment deraf; og genvinding af antistoffet, eller det antigenbindende fragment deraf, fra værtscellen eller dyrkningsmediet.
DK06802592.3T 2005-08-31 2006-08-29 Konstruerede anti-il-23-antistoffer DK1931710T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71358505P 2005-08-31 2005-08-31
PCT/US2006/033764 WO2007027714A2 (en) 2005-08-31 2006-08-29 Engineered anti-il-23 antibodies

Publications (1)

Publication Number Publication Date
DK1931710T3 true DK1931710T3 (da) 2017-04-03

Family

ID=37685722

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06802592.3T DK1931710T3 (da) 2005-08-31 2006-08-29 Konstruerede anti-il-23-antistoffer

Country Status (17)

Country Link
US (3) US7807160B2 (da)
EP (3) EP2354160A1 (da)
JP (2) JP5350793B2 (da)
CN (1) CN101296944A (da)
CA (1) CA2620802A1 (da)
CY (2) CY1118760T1 (da)
DK (1) DK1931710T3 (da)
ES (1) ES2619845T3 (da)
HR (1) HRP20170444T1 (da)
HU (2) HUE032131T2 (da)
LT (2) LT1931710T (da)
ME (1) ME02705B (da)
PL (1) PL1931710T3 (da)
PT (1) PT1931710T (da)
RS (1) RS55788B1 (da)
SG (2) SG165322A1 (da)
WO (1) WO2007027714A2 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2452694T (pt) * 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
EP2354160A1 (en) * 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
EP2116258A1 (en) 2005-09-01 2009-11-11 Schering Corporation Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
ES2547689T3 (es) * 2005-12-02 2015-10-08 Genentech, Inc. Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R
KR101210395B1 (ko) * 2005-12-29 2012-12-11 얀센 바이오테크 인코포레이티드 인간 항-ｉｌ-23 항체, 조성물, 방법 및 용도
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
WO2007147019A2 (en) * 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
US8414897B1 (en) * 2006-10-02 2013-04-09 The Uab Research Foundation Pathway for Th-17 cell development and methods utilizing same
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
MX2009009080A (es) 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
TR201821029T4 (tr) 2007-02-23 2019-01-21 Merck Sharp & Dohme Geliştirilmiş antı-IL-23p19 antikorları.
CN101668531B (zh) 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
EP2395025A1 (en) 2007-02-28 2011-12-14 Schering Corporation Engineered Anti-IL-23R Antibodies
WO2009033095A2 (en) * 2007-09-07 2009-03-12 Cisthera, Incorporated Humanized pai-1 antibodies
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies
US20100203009A1 (en) * 2007-10-02 2010-08-12 The Uab Research Foundation Pathway for Th-17 Cell Development and Methods Utilizing Same
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
AU2009204441B2 (en) * 2008-01-09 2015-03-05 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of ocular inflammatory disorders
WO2010017598A1 (en) 2008-08-14 2010-02-18 Arana Therapeutics Limited Anti-il-12/il-23 antibodies
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
US8618264B2 (en) * 2008-09-29 2013-12-31 Centocor Ortho Biotech Inc. Anti-CD147 antibodies, methods and uses
EP2379710A1 (en) * 2008-12-19 2011-10-26 Schering Corporation Feed supplement for mammalian cell culture and methods of use
WO2010127181A1 (en) * 2009-04-29 2010-11-04 Trellis Bioscience, Inc. Improved antibodies immunoreactive with heregulin-coupled her3
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
SG177025A1 (en) 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
LT3789038T (lt) * 2010-05-14 2022-12-12 The Board Of Trustees Of The Leland Stanford Junior University Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CN103108886B (zh) 2010-07-20 2016-08-24 赛法隆澳大利亚控股有限公司 抗il-23杂二聚体特异性抗体
EP3456740A1 (en) * 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
EP2675467A4 (en) * 2011-02-18 2014-06-25 Merck Sharp & Dohme USE OF MDL-1 ANTAGONISTS FOR TREATING SPONDYLARTHROPATHY
EP2583979B1 (en) 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
BR112014019331A2 (pt) 2012-02-06 2022-07-12 Inhibrx Inc anticorpos para cd47 e métodos de uso desses
EA201401204A1 (ru) 2012-05-03 2015-05-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитела к il-23p19
US9708401B2 (en) 2012-05-22 2017-07-18 Bristol-Myers Squibb Company IL-17A/F cross-reactive monoclonal antibodies and methods of using the same
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
CA2906384A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
SG11201507482UA (en) 2013-03-15 2015-10-29 Amgen Inc Methods for treating psoriasis using an anti-il-23 antibody
RU2725825C2 (ru) 2013-08-30 2020-07-06 Иммьюноджен Инк. Антитела и методы анализа для обнаружения рецептора фолиевой кислоты 1
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
KR102523914B1 (ko) 2014-09-03 2023-04-19 베링거잉겔하임인터내쇼날유한회사 Il-23a 및 tnf-알파를 표적으로 하는 화합물 및 이의 용도
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
MX2017010037A (es) 2015-02-04 2018-05-15 Boehringer Ingelheim Int Metodos de tratamiento de enfermedades inflamatorias.
EP3685856A1 (en) 2015-04-14 2020-07-29 Boehringer Ingelheim International GmbH Treatment of asthma with anti-il-23a antibodies
AU2016271857B2 (en) * 2015-06-03 2020-05-28 Affiris Ag IL-23-P19 vaccines
EP3349796A4 (en) 2015-09-17 2019-05-29 ImmunoGen, Inc. THERAPEUTIC COMBINATIONS COMPRISING ANTI-FOLR1 IMMUNOCONJUGATES
CN108290058B (zh) 2015-09-17 2023-05-16 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
TWI733695B (zh) * 2015-09-18 2021-07-21 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
JP2019508370A (ja) 2015-12-22 2019-03-28 アムジェン インコーポレイテッド Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０
MX2018012410A (es) 2016-04-15 2019-02-21 Boehringer Ingelheim Int Metodos para tratar enfermedades inflamatorias.
IL299099A (en) 2016-06-27 2023-02-01 Univ California Combinations of cancer treatments
EP4032906A1 (en) 2016-10-14 2022-07-27 Boehringer Ingelheim International GmbH Methods of treating diseases
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3618871A4 (en) 2017-05-02 2021-01-06 Merck Sharp & Dohme Corp. ANTI-LAG3 ANTIBODIES ETCO-FORMULATIONS ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
US11845797B2 (en) 2018-07-03 2023-12-19 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3105598A1 (en) 2018-07-13 2020-01-16 Carl GOMMOLL Treating ulcerative colitis with brazikumab
US20200025776A1 (en) * 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2022537780A (ja) 2019-06-21 2022-08-29 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
JP2022538083A (ja) 2019-06-21 2022-08-31 ソリッソ ファーマシューティカルズ，インク． ポリペプチド
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
JP2023509373A (ja) 2019-12-20 2023-03-08 ノヴァロック バイオセラピューティクス， リミテッド 抗インターロイキン－２３ ｐ１９抗体およびそれの使用方法
WO2021138409A2 (en) * 2019-12-31 2021-07-08 Medstar Health, Inc. Anti-cd160 binding molecules for treating diseases
CN113698480B (zh) * 2021-09-18 2022-07-01 东大生物技术(苏州)有限公司 一组il-23单克隆抗体及其医药用途

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US6096289A (en) * 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162823T5 (es) 1992-08-21 2010-08-09 Vrije Universiteit Brussel Inmunoglobulinas desprovistas de cadenas ligeras.
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1997003715A1 (en) 1995-07-21 1997-02-06 The General Hospital Corporation Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
DE69942607D1 (de) 1998-04-14 2010-09-02 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
CA2366706A1 (en) 1999-03-11 2000-09-14 Schering Corporation Mammalian cytokines; related reagents and methods
HU230679B1 (en) 1999-09-09 2017-08-28 Merck Sharp & Dohme Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
DE60328823D1 (de) 2002-10-30 2009-09-24 Genentech Inc Hemmung von il-17 produktion
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
BRPI0408247A (pt) 2003-03-10 2006-03-01 Schering Corp usos de antagonistas e agonistas de il-23 e reagentes relacionados
EP1623011B1 (en) 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
ES2630224T3 (es) 2003-10-22 2017-08-18 Keck Graduate Institute Métodos para sintetizar polipéptidos heteromultiméricos en levadura con el uso de una estrategia de apareamiento haploide
WO2005047324A2 (en) 2003-11-10 2005-05-26 Schering Corp ANTI-INTERLEUKIN ANTIBODY-10
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
EP1766396B1 (en) 2004-06-07 2010-08-11 Ramot at Tel-Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
PT2452694T (pt) * 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
CA2619052A1 (en) * 2005-08-25 2007-03-01 Eli Lily And Company Anti-il-23 antibiodies
EP2354160A1 (en) 2005-08-31 2011-08-10 Schering Corporation Engineered anti-IL-23-antibodies
KR101210395B1 (ko) 2005-12-29 2012-12-11 얀센 바이오테크 인코포레이티드 인간 항-ｉｌ-23 항체, 조성물, 방법 및 용도

Also Published As

Publication number Publication date
ES2619845T3 (es) 2017-06-27
EP1931710A2 (en) 2008-06-18
EP1931710B1 (en) 2017-01-18
CY1118760T1 (el) 2017-07-12
JP5350793B2 (ja) 2013-11-27
US20090156788A1 (en) 2009-06-18
JP2009505677A (ja) 2009-02-12
US7807160B2 (en) 2010-10-05
RS55788B1 (sr) 2017-08-31
HUE032131T2 (en) 2017-09-28
PT1931710T (pt) 2017-03-28
US20070048315A1 (en) 2007-03-01
ME02705B (me) 2017-10-20
HRP20170444T1 (hr) 2017-05-19
WO2007027714A3 (en) 2007-06-21
CN101296944A (zh) 2008-10-29
LTPA2019520I1 (lt) 2019-11-11
CY2019041I2 (el) 2020-05-29
PL1931710T3 (pl) 2017-06-30
CA2620802A1 (en) 2007-03-08
US8362212B2 (en) 2013-01-29
SG165322A1 (en) 2010-10-28
CY2019041I1 (el) 2020-05-29
EP3190125A1 (en) 2017-07-12
HUS1900050I1 (hu) 2019-11-28
EP2354160A1 (en) 2011-08-10
JP2011130771A (ja) 2011-07-07
SG10201402712QA (en) 2014-08-28
WO2007027714A2 (en) 2007-03-08
LT1931710T (lt) 2017-03-27
US20110002942A1 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
DK1931710T3 (da) Konstruerede anti-il-23-antistoffer
US8513389B2 (en) Engineered anti-IL-23p19 antibodies
AU2008218968B2 (en) Engineered anti-IL-23p19 antibodies